Lin Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lin Bioscience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11120
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lin Bioscience Inc (Lin Bioscience) is a drug development company that specializes in developing therapies for oncology, ophthalmology and other metabolic diseases. The company’s pipeline product LBS-008 is an oral therapy for treatment of macular degeneration; LBS-007 is a small molecular inhibitor for treatment of cancer, and LBS-002 is an anti tubulin for the treatment of primary and metastatic brain tumors. Its pipeline products aim to find therapies for AMDStargardt disease, acute leukemia solid tumors, triple negative breast cancer and glioblastomabrain metastasis. Lin Bioscience is headquartered in Taipei City, Taiwan.

Lin Bioscience Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lin Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 7
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 9
Licensing Agreements 9
Lin BioScience Enters into Licensing Agreement with University of Sydney 9
Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 10
Lin Bioscience Enters into Licensing Agreement with Columbia Technology Ventures 11
Lin Bioscience Inc – Key Competitors 12
Lin Bioscience Inc – Key Employees 13
Lin Bioscience Inc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Recent Developments 15
Product Approvals 15
Sep 18, 2018: FDA grants Lin BioScience Rare Pediatric Disease status for LBS-008 to treat Stargardt Disease 15
Jun 27, 2018: Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease 16
Clinical Trials 17
Oct 26, 2017: Lin BioScience Receives US FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lin Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lin Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 7
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Lin BioScience Enters into Licensing Agreement with University of Sydney 9
Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 10
Lin Bioscience Enters into Licensing Agreement with Columbia Technology Ventures 11
Lin Bioscience Inc, Key Competitors 12
Lin Bioscience Inc, Key Employees 13
Lin Bioscience Inc, Other Locations 14

List of Figures
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 7

★海外企業調査レポート[Lin Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Molnlycke Health Care AB-医療機器分野:企業M&A・提携分析
    Summary Molnlycke Health Care AB (Molnlycke) a subsidiary of Investor AB, is a medical device company. The company carries out the manufacturing and marketing of single-use surgical and wound care products. The company offers a range of surgical and wound care products; infection prevention solution …
  • MetGen Oy:製薬・医療:M&Aディール及び事業提携情報
    Summary MetGen Oy (MetGen) is a manufacturer and distributor of enzymatic solutions. The company offers metzyme, an industrial and natural catalysts used for accelerating chemical reactions. Its enzymatic solutions find applications in various processes such as mechanical processes, lignocellulosic …
  • Coutts & Co:企業の戦略・SWOT・財務情報
    Coutts & Co - Strategy, SWOT and Corporate Finance Report Summary Coutts & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • West Pharmaceutical Services Inc (WST):企業の財務・戦略的SWOT分析
    West Pharmaceutical Services Inc (WST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Kinder Morgan, Inc.:企業の戦略・SWOT・財務分析
    Kinder Morgan, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kinder Morgan, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sun Pharma Advanced Research Company Ltd (SPARC):企業の財務・戦略的SWOT分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatme …
  • XCyton Diagnostics Ltd-医療機器分野:企業M&A・提携分析
    Summary XCyton Diagnostics Ltd (Xcyton) is a molecular biology company that develops and markets diagnostics products and services. The company provides ELISA kit for the detection of HIV infection; ELISA products for the detection of Neurocysticercosis, Hepatitis C and Japanese encephalitis. It pro …
  • Symrise AG (SY1):製薬・医療:M&Aディール及び事業提携情報
    Summary Symrise AG (Symrise) offers flavors and fragrances. The company develops, produces and sells flavorings, fragrances, cosmetic active ingredients and raw materials, and functional ingredients and solutions for the cosmetics industry. It also provides biofunctional and bioactive ingredients an …
  • ARYZTA AG:企業のM&A・事業提携・投資動向
    ARYZTA AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ARYZTA AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Lansdowne Oil & Gas plc (LOGP):企業の財務・戦略的SWOT分析
    Summary Lansdowne Oil & Gas Plc (Lansdowne Oil & Gas) is an independent oil and gas exploration and production company. The company acquires, explores and develops crude oil and natural gas appraisals in the North Celtic Sea Basin offshore in southern Ireland. It develops Barryroe Field in the North …
  • NII Holdings, Inc.:戦略・SWOT・企業財務分析
    NII Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary NII Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ResApp Health Ltd (RAP):企業の製品パイプライン分析
    Summary ResApp Health Ltd (ResApp) formerly, Narhex Life Sciences Limited is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseas …
  • Impax Laboratories Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Impax Laboratories Inc (Impax) develops, manufactures and markets generic and branded pharmaceuticals. It offers solid dose and alternative dosage form generic drugs in a broad range of therapeutic areas; and proprietary branded pharmaceutical products for the treatment of central nervous sy …
  • adidas AG (ADS):企業の財務・戦略的SWOT分析
    adidas AG (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Kura Oncology Inc (KURA):企業の財務・戦略的SWOT分析
    Summary Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candi …
  • SmartCool Systems Inc (SSC):企業の財務・戦略的SWOT分析
    Summary SmartCool Systems Inc (SmartCool Systems) is a clean technology company that manufactures and sells energy and cost reduction technologies. The company’s products include ECO3, ESM, and soft solutions. Its ECO3 and ESM are retrofit technologies that reduce the energy consumption of compresso …
  • Impax Laboratories Inc (IPXL)-製薬・医療分野:企業M&A・提携分析
    Summary Impax Laboratories Inc (Impax) develops, manufactures and markets generic and branded pharmaceuticals. It offers solid dose and alternative dosage form generic drugs in a broad range of therapeutic areas; and proprietary branded pharmaceutical products for the treatment of central nervous sy …
  • Duvel Moortgat NV:企業の戦略的SWOT分析
    Duvel Moortgat NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ProQR Therapeutics NV (PRQR):企業の財務・戦略的SWOT分析
    Summary ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide …
  • Zenrosai:企業の戦略・SWOT・財務情報
    Zenrosai - Strategy, SWOT and Corporate Finance Report Summary Zenrosai - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆